Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1103696

Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920


Skelin, Marko; Rahelić, Dario; Skelin, Petar; Lucijanic, Marko
Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 // Diabetes Care, 43 (2020), 2; e28-e29 doi:10.2337/dc19-2039 (međunarodna recenzija, pismo uredniku, znanstveni)


CROSBI ID: 1103696 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920

Autori
Skelin, Marko ; Rahelić, Dario ; Skelin, Petar ; Lucijanic, Marko

Izvornik
Diabetes Care (0149-5992) 43 (2020), 2; E28-e29

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, znanstveni

Ključne riječi
liraglutide ; diabetes

Sažetak
The pitfall of performing statistical analysis regarding retrospective survival analysis is that the investigators should considered an issue of competing risks. Competing risk appears when one of the events can prevent or modify the chance of occurrence of the event of interest. The researchers using the standard method of survival analysis (Cox regression) for their time-to-event analysis, actually use suboptimal method due to the fact that it wrongly presumes random and noninformative censoring (independent of the event of interest) However, censoring due to death is informative as it precludes the event of interest from occurring. As a result, we can expect falsely higher estimates of the event of interest in the group with less censoring, in this case the liraglutide group. The method for competing risk analysis, such as the method developed by Fine and Gray takes into consideration informative censoring together with all the observed events. Consequently, it interprets the effect of interest depending on the magnitude of the risk of other competing events.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Opća bolnica Šibenik,
Klinička bolnica "Dubrava"

Profili:

Avatar Url Dario Rahelić (autor)

Avatar Url Marko Skelin (autor)

Avatar Url Marko Lucijanic (autor)

Poveznice na cjeloviti tekst rada:

doi care.diabetesjournals.org

Citiraj ovu publikaciju:

Skelin, Marko; Rahelić, Dario; Skelin, Petar; Lucijanic, Marko
Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 // Diabetes Care, 43 (2020), 2; e28-e29 doi:10.2337/dc19-2039 (međunarodna recenzija, pismo uredniku, znanstveni)
Skelin, M., Rahelić, D., Skelin, P. & Lucijanic, M. (2020) Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920. Diabetes Care, 43 (2), e28-e29 doi:10.2337/dc19-2039.
@article{article, author = {Skelin, Marko and Raheli\'{c}, Dario and Skelin, Petar and Lucijanic, Marko}, year = {2020}, pages = {e28-e29}, DOI = {10.2337/dc19-2039}, keywords = {liraglutide, diabetes}, journal = {Diabetes Care}, doi = {10.2337/dc19-2039}, volume = {43}, number = {2}, issn = {0149-5992}, title = {Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920}, keyword = {liraglutide, diabetes} }
@article{article, author = {Skelin, Marko and Raheli\'{c}, Dario and Skelin, Petar and Lucijanic, Marko}, year = {2020}, pages = {e28-e29}, DOI = {10.2337/dc19-2039}, keywords = {liraglutide, diabetes}, journal = {Diabetes Care}, doi = {10.2337/dc19-2039}, volume = {43}, number = {2}, issn = {0149-5992}, title = {Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920}, keyword = {liraglutide, diabetes} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font